Market Research Logo

Moderate Psoriasis - Pipeline Review, H2 2015

Moderate Psoriasis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Moderate Psoriasis - Pipeline Review, H2 2015’, provides an overview of the Moderate Psoriasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Moderate Psoriasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Moderate Psoriasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Moderate Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Moderate Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Moderate Psoriasis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Moderate Psoriasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Moderate Psoriasis Overview
Therapeutics Development
Pipeline Products for Moderate Psoriasis - Overview
Moderate Psoriasis - Therapeutics under Development by Companies
Moderate Psoriasis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Moderate Psoriasis - Products under Development by Companies
Moderate Psoriasis - Companies Involved in Therapeutics Development
AbGenomics International, Inc.
ADC Therapeutics Sarl
Almirall, S.A.
AstraZeneca Plc
Avexxin AS
Boehringer Ingelheim GmbH
Celgene Corporation
Convoy Therapeutics, Inc.
Crescendo Biologics Limited
Delenex Therapeutics AG
Eli Lilly and Company
Forward Pharma A/S
Galectin Therapeutics, Inc.
GlycoMar Limited
Idera Pharmaceuticals, Inc.
Johnson & Johnson
Merck KGaA
OPKO Health, Inc.
Sandoz International GmbH
Soligenix, Inc.
Sun Pharma Advanced Research Company Ltd.
Syntrix Biosystems, Inc.
Valeant Pharmaceuticals International, Inc.
Moderate Psoriasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(halobetasol propionate + tazarotene) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AbGn-168H - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AKP-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aminopterin sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AVX-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
baricitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BI-655066 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brodalumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC-90005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COVA-322 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclosporine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dimethyl fumarate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dimethyl fumarate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DLX-105 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLY-2028 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GRMD-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
guselkumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMO-8400 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ixekizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lunacalcipol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
M-1095 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
orilotimod potassium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SGX-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tazarotene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tildrakizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
toreforant tartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VM-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Moderate Psoriasis - Recent Pipeline Updates
Moderate Psoriasis - Dormant Projects
Moderate Psoriasis - Discontinued Products
Moderate Psoriasis - Product Development Milestones
Featured News & Press Releases
Sep 11, 2014: Delenex Announces New Clinical Data
Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Moderate Psoriasis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Moderate Psoriasis - Pipeline by AbGenomics International, Inc., H2 2015
Moderate Psoriasis - Pipeline by ADC Therapeutics Sarl, H2 2015
Moderate Psoriasis - Pipeline by Almirall, S.A., H2 2015
Moderate Psoriasis - Pipeline by AstraZeneca Plc, H2 2015
Moderate Psoriasis - Pipeline by Avexxin AS, H2 2015
Moderate Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Moderate Psoriasis - Pipeline by Celgene Corporation, H2 2015
Moderate Psoriasis - Pipeline by Convoy Therapeutics, Inc., H2 2015
Moderate Psoriasis - Pipeline by Crescendo Biologics Limited, H2 2015
Moderate Psoriasis - Pipeline by Delenex Therapeutics AG, H2 2015
Moderate Psoriasis - Pipeline by Eli Lilly and Company, H2 2015
Moderate Psoriasis - Pipeline by Forward Pharma A/S, H2 2015
Moderate Psoriasis - Pipeline by Galectin Therapeutics, Inc., H2 2015
Moderate Psoriasis - Pipeline by GlycoMar Limited, H2 2015
Moderate Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H2 2015
Moderate Psoriasis - Pipeline by Johnson & Johnson, H2 2015
Moderate Psoriasis - Pipeline by Merck KGaA, H2 2015
Moderate Psoriasis - Pipeline by OPKO Health, Inc., H2 2015
Moderate Psoriasis - Pipeline by Sandoz International GmbH, H2 2015
Moderate Psoriasis - Pipeline by Soligenix, Inc., H2 2015
Moderate Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
Moderate Psoriasis - Pipeline by Syntrix Biosystems, Inc., H2 2015
Moderate Psoriasis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Moderate Psoriasis Therapeutics - Recent Pipeline Updates, H2 2015
Moderate Psoriasis - Dormant Projects, H2 2015
Moderate Psoriasis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Moderate Psoriasis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report